SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS (Nasdaq: SOPH) priced a previously announced underwritten public offering of 10,526,000 ordinary shares at $4.75 each, raising about $50 million in gross proceeds, according to the company. It also granted underwriters a 30-day option to buy up to 1,578,900 additional shares. The offering is expected to close June 18, 2026.
How this was made
The 30-second read
Why it matters
The key tradable elements are the fixed offering price ($4.75), share count (10.526M plus up to 1.579M option), and the close date (June 18). These drive dilution expectations and potential supply overhang into/after settlement.
Market read
A priced equity raise of ~$50M (plus greenshoe) is a concrete capital-markets event that can move the stock via dilution/supply dynamics.
What to watch
The article doesn’t state use of proceeds, underwriting discount, or any concurrent buyback/financing hedges; those details can materially change the net impact on valuation and near-term trading.
Background
SOPHiA GENETICS announced and priced an underwritten public offering under an already-effective Form F-3 registration statement.
Ticker impact
SOPHiA GENETICS priced an underwritten public offering of 10,526,000 ordinary shares at $4.75, raising ~$50M gross proceeds.
Near-term downside/volatility risk around offering execution; longer-term direction depends on stated use of proceeds (not provided here).
The article discloses the offering size, price, and expected close date, which are direct inputs to dilution and supply overhang expectations. It does not disclose proceeds use, so longer-term fundamental impact is uncertain.
Market effects
Adds to the broader biotech/health-tech financing backdrop where equity issuance can reset risk appetite for pre-profit growth names.
Limited; this is a US-listed issuer with global operations, but the transaction is executed in US capital markets.
Low; the offering is not described as tied to a global regulatory or commercial milestone.
Counterpoint
If the company uses proceeds to accelerate revenue-generating deployments or reduce balance-sheet risk, the offering could be viewed as supportive rather than dilutive.
Key entities
- companySOPHiA GENETICS
Nasdaq-listed precision medicine technology company pricing an underwritten public offering.
- financial_institutionTD Cowen
Lead book-running manager for the offering.
- financial_institutionGuggenheim Securities
Book-running manager for the offering.
